A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B (CHB)

Inclusion Criteria: * Male or female, 18 to 55 years of age inclusive (NHVs) or 18-65 years of age inclusive (CHBs), at the time of informed consent * Able to provide written informed consent prior to the performance of any study specific procedures * Body mass index (BMI) between 19.0 and 35.0 kg/m2, inclusive * A 12-lead ECG at Screening and pre-dose assessment that, in the opinion of the investigator, has no abnormalities that compromise participant's safety in this study * Must use 2 effective methods of contraception (double barrier contraception or hormonal contraceptive along with a barrier contraceptive (both male and female partners) * Have suitable venous access for blood sampling * No abnormal finding of clinical relevance at the Screening evaluation (NHVs only) * Have a diagnosis of HbeAg-negative chronic HBV infection (CHB patients only) * Treatment-naive or currently on entecavir/tenofovir for 6 months or longer Exclusion Criteria: * Pregnant or lactating * Acute signs of hepatitis/other infection at Screening or at baseline * Use within last 14 days or anticipated requirement for anticoagulants, systemic corticosteroids, immunomodulators, or immunosuppressants * Use of prescription medication within 14 days prior to study treatment that in the opinion of the PI or the Sponsor would interfere with study conduct. * Known diagnosis of non-alcoholic steatohepatitis \[NHVs only\] or familial hypercholesterolemia * Taking interferon alpha (INFalpha) within 6 month…